{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T19:13:06Z","timestamp":1780686786243,"version":"3.54.1"},"reference-count":141,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,7]],"date-time":"2021-10-07T00:00:00Z","timestamp":1633564800000},"content-version":"vor","delay-in-days":279,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2021]]},"DOI":"10.1016\/j.ctarc.2021.100473","type":"journal-article","created":{"date-parts":[[2021,10,12]],"date-time":"2021-10-12T17:45:35Z","timestamp":1634060735000},"page":"100473","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"special_numbering":"C","title":["Oncolytic virotherapy \u2013 Forging its place in the immunomodulatory paradigm for Multiple Myeloma"],"prefix":"10.1016","volume":"29","author":[{"given":"Joselle","family":"Cook","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aldo A.","family":"Acosta-Medina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kah Whye","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martha","family":"Lacy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Russell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctarc.2021.100473_bib0001","doi-asserted-by":"crossref","first-page":"8039","DOI":"10.1200\/JCO.2019.37.15_suppl.8039","article-title":"Continued improvement in survival in multiple myeloma (MM) including high-risk patients","volume":"37","author":"Nandakumar","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0002","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0003","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1182\/blood-2002-03-0996","article-title":"Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma","volume":"100","author":"Richardson","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0004","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"Miguel","year":"2013","journal-title":"Lancet. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0005","doi-asserted-by":"crossref","first-page":"e447","DOI":"10.1016\/S2352-3026(20)30081-8","article-title":"Daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma: final results from the phase 2 GEN501 and SIRIUS trials","volume":"7","author":"Usmani","year":"2020","journal-title":"Lancet. Haematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0006","doi-asserted-by":"crossref","first-page":"e103","DOI":"10.1002\/j.1875-9114.2012.01036.x","article-title":"Hemopericardium in a patient treated with dabigatran etexilate","volume":"32","author":"Barton","year":"2012","journal-title":"Pharmacotherapy"},{"key":"10.1016\/j.ctarc.2021.100473_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/S0140-6736(19)31240-1","article-title":"Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study","author":"Moreau","year":"2019","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100473_bib0008","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1056\/NEJMoa1817249","article-title":"Daratumumab plus lenalidomide and dexamethasone for untreated myeloma","volume":"380","author":"Facon","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0009","article-title":"Shine in multiple myeloma","volume":"11","year":"2021","journal-title":"Cancer Discov"},{"key":"10.1016\/j.ctarc.2021.100473_bib0010","article-title":"B-cell maturation antigen (BCMA) in multiple myeloma: the new frontier of targeted therapies. Ther","volume":"12","author":"Sanchez","year":"2021","journal-title":"Adv. Hematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0011","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1080\/14712598.2020.1802422","article-title":"Antibody-drug conjugates for multiple myeloma","volume":"21","author":"McMillan","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0012","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1097\/00000441-190412740-00001","article-title":"Influence of complicating diseases upon leukemia","volume":"127","author":"Dock","year":"1904","journal-title":"Am. J. Med. Sci."},{"key":"10.1016\/j.ctarc.2021.100473_bib0013","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/S0140-6736(71)92086-1","article-title":"Regression of burkitt's lymphoma in association with measles infection","volume":"298","author":"Bluming","year":"1971","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ctarc.2021.100473_bib0014","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1016\/S0140-6736(71)91186-X","article-title":"Hodgkin\u2019s disease: remissions after measles","author":"Zygiert","year":"1971","journal-title":"Lancet"},{"key":"10.1016\/j.ctarc.2021.100473_bib0015","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1002\/1097-0142(195305)6:3<591::AID-CNCR2820060317>3.0.CO;2-M","article-title":"Remissions in leukemia of childhood following acute infectious disease: staphylococcus and streptococcus, varicella, and feline panleukopenia","volume":"6","author":"Bierman","year":"1953","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0016","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1038\/sj.mt.6300108","article-title":"History of oncolytic viruses: genesis to genetic engineering","volume":"15","author":"Kelly","year":"2007","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0017","doi-asserted-by":"crossref","first-page":"2652","DOI":"10.1007\/s00259-021-05275-6","article-title":"Complete remission of follicular lymphoma after SARS-CoV-2 infection: from the \u201cflare phenomenon\u201d to the \u201cabscopal effect","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.ctarc.2021.100473_bib0018","doi-asserted-by":"crossref","DOI":"10.1111\/bjh.17116","article-title":"SARS-CoV-2-induced remission of Hodgkin lymphoma","author":"Challenor","year":"2021","journal-title":"Br. J. Haematol"},{"key":"10.1016\/j.ctarc.2021.100473_bib0019","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1126\/science.1851332","article-title":"Experimental therapy of human glioma by means of a genetically engineered virus mutant","volume":"252","author":"Martuza","year":"1991","journal-title":"Science (80-.)."},{"key":"10.1016\/j.ctarc.2021.100473_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2021.111573","article-title":"Oncolytic viruses as a promising therapeutic strategy for hematological malignancies","volume":"139","author":"Yang","year":"2021","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.ctarc.2021.100473_bib0021","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic Viruses and immune checkpoint inhibitors: preclinical developments to clinical trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2021.100473_bib0022","doi-asserted-by":"crossref","first-page":"558","DOI":"10.3390\/v10100558","article-title":"Systemic administration and targeted delivery of immunogenic oncolytic adenovirus encapsulated in extracellular vesicles for cancer therapies","volume":"10","author":"Garofalo","year":"2018","journal-title":"Viruses"},{"key":"10.1016\/j.ctarc.2021.100473_bib0023","doi-asserted-by":"crossref","first-page":"106","DOI":"10.3389\/fonc.2017.00106","article-title":"Immune system, friend or foe of oncolytic virotherapy?","volume":"vol. 7","author":"Filley","year":"2017","journal-title":"Front Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0024","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.omto.2017.03.002","article-title":"Combining Oncolytic Virotherapy with p53 Tumor Suppressor Gene Therapy","volume":"5","author":"Bressy","year":"2017","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.ctarc.2021.100473_bib0025","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.cell.2018.03.035","article-title":"Oncogenic signaling pathways in the cancer genome atlas","volume":"173","author":"Sanchez-Vega","year":"2018","journal-title":"Cell"},{"key":"10.1016\/j.ctarc.2021.100473_bib0026","doi-asserted-by":"crossref","first-page":"14981","DOI":"10.1073\/pnas.0803988105","article-title":"Chemical targeting of the innate antiviral response by histone deacetylase inhibitors renders refractory cancers sensitive to viral oncolysis","volume":"105","author":"Nguy\u00ean","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ctarc.2021.100473_bib0027","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.trecan.2015.10.004","article-title":"Oncolytic viruses: exploiting cancer\u2019s deal with the devil","volume":"1","author":"Pikor","year":"2015","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0028","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/S1535-6108(03)00241-1","article-title":"VSV strains with defects in their ability to shutdown innate immunity are potent systemic anti-cancer agents","volume":"4","author":"Stojdl","year":"2003","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ctarc.2021.100473_bib0029","doi-asserted-by":"crossref","first-page":"866","DOI":"10.3389\/fimmu.2018.00866","article-title":"Oncolytic viral therapy and the immune system: a double-edged sword against cancer","volume":"vol. 9","author":"Marelli","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0030","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1016\/j.ymthe.2020.09.016","article-title":"Gene editing thumbs a ride with oncolytic virotherapy","volume":"28","author":"Wang","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0031","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.jvir.2013.05.040","volume":"24","author":"Sze","year":"2013","journal-title":"J. Vasc. Interv. Radiol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0032","doi-asserted-by":"crossref","first-page":"e73759","DOI":"10.1371\/journal.pone.0073759","article-title":"Mathematical model for radial expansion and conflation of intratumoral infectious centers predicts curative oncolytic virotherapy parameters","volume":"8","author":"Bailey","year":"2013","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2021.100473_bib0033","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic viruses and the immune system: the dynamic duo","volume":"17","author":"Lemos de Matos","year":"2020","journal-title":"Mol. Ther. - Methods Clin. Dev."},{"key":"10.1016\/j.ctarc.2021.100473_bib0034","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1002\/ajh.21444","article-title":"Tumor-associated macrophages infiltrate plasmacytomas and can serve as cell carriers for oncolytic measles virotherapy of disseminated myeloma","volume":"84","author":"Peng","year":"2009","journal-title":"Am J Hematol"},{"key":"10.1016\/j.ctarc.2021.100473_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtm.2020.01.001","article-title":"Oncolytic Viruses and the immune system: the dynamic duo","author":"Lemos de Matos","year":"2020","journal-title":"molecular therapy - methods and clinical development"},{"key":"10.1016\/j.ctarc.2021.100473_bib0036","doi-asserted-by":"crossref","DOI":"10.1038\/s41375-020-0828-7","article-title":"Oncolytic measles virus therapy enhances tumor antigen-specific T-cell responses in patients with multiple myeloma","author":"Packiriswamy","year":"2020","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100473_bib0037","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1097\/CCO.0000000000000615","article-title":"The microenvironment in myeloma","volume":"32","author":"Lomas","year":"2020","journal-title":"Curr. Opin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0038","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20112822","article-title":"Lymphocyte subsets and inflammatory cytokines of monoclonal gammopathy of undetermined significance and multiple myeloma","volume":"20","author":"Allegra","year":"2019","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2021.100473_bib0039","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1038\/sj.leu.2404096","article-title":"Impaired activating receptor expression pattern in natural killer cells from patients with multiple myeloma","volume":"20","author":"Fauriat","year":"2006","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100473_bib0040","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1111\/j.1365-2141.2012.09154.x","article-title":"Macrophages and mesenchymal stromal cells support survival and proliferation of multiple myeloma cells","volume":"158","author":"Kim","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0041","doi-asserted-by":"crossref","first-page":"3625","DOI":"10.1182\/blood-2009-05-220285","article-title":"Macrophages are an abundant component of myeloma microenvironment and protect myeloma cells from chemotherapy drug-induced apoptosis","volume":"114","author":"Zheng","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0042","doi-asserted-by":"crossref","first-page":"3940","DOI":"10.1182\/blood-2005-09-3671","article-title":"In vivo peripheral expansion of naive CD4+CD25high FoxP3+ regulatory T cells in patients with multiple myeloma","volume":"107","author":"Beyer","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0043","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1080\/10245330310001652437","article-title":"Th1\/Th2 cells in patients with multiple myeloma","volume":"9","author":"Murakami","year":"2004","journal-title":"Hematology"},{"key":"10.1016\/j.ctarc.2021.100473_bib0044","doi-asserted-by":"crossref","first-page":"2286","DOI":"10.1182\/blood-2010-02-271874","article-title":"The PD-1\/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody","volume":"116","author":"Benson","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0045","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2015.7","article-title":"Immunomodulatory molecule PD-L1 is expressed on malignant plasma cells and myeloma-propagating pre-plasma cells in the bone marrow of multiple myeloma patients","volume":"5","author":"Yousef","year":"2015","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctarc.2021.100473_bib0046","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1182\/blood-2008-10-184226","article-title":"Induction of angiogenesis by normal and malignant plasma cells","volume":"114","author":"Hose","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0047","doi-asserted-by":"crossref","first-page":"4257","DOI":"10.1038\/sj.onc.1209456","article-title":"Importance of the bone marrow microenvironment in inducing the angiogenic response in multiple myeloma","volume":"25","author":"Ribatti","year":"2006","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2021.100473_bib0048","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/nrc2189","article-title":"Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets","volume":"7","author":"Hideshima","year":"2007","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0049","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22052259","article-title":"Oncolytic virotherapy and microenvironment in multiple myeloma","volume":"22","author":"Marchica","year":"2021","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.ctarc.2021.100473_bib0050","doi-asserted-by":"crossref","first-page":"168","DOI":"10.3389\/fimmu.2019.00168","article-title":"Cold tumors: a therapeutic challenge for immunotherapy","volume":"vol. 10","author":"Bonaventura","year":"2019","journal-title":"Front Immunol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0051","article-title":"Oncolytic viruses as engineering platforms for combination immunotherapy","author":"Twumasi-Boateng","year":"2018","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0052","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.coviro.2020.07.016","article-title":"Measles virus in cancer therapy","volume":"41","author":"M\u00fchlebach","year":"2020","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0053","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1080\/17425247.2019.1617269","article-title":"Achieving systemic delivery of oncolytic viruses","volume":"16","author":"Hill","year":"2019","journal-title":"Expert Opin. Drug Deliv."},{"key":"10.1016\/j.ctarc.2021.100473_bib0054","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrmicro1927","article-title":"Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded","volume":"6","author":"Cattaneo","year":"2008","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0055","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1038\/nm0502-527","article-title":"Non-invasive in vivo monitoring of trackable viruses expressing soluble marker peptides","volume":"8","author":"Peng","year":"2002","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0056","doi-asserted-by":"crossref","first-page":"32174","DOI":"10.1038\/srep32174","article-title":"Combined expression of miR-34a and Smac mediated by oncolytic vaccinia virus synergistically promote anti-tumor effects in Multiple Myeloma","volume":"6","author":"Lei","year":"2016","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2021.100473_bib0057","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/s41467-017-00324-x","article-title":"Smac mimetics and oncolytic viruses synergize in driving anticancer T-cell responses through complementary mechanisms","volume":"8","author":"Kim","year":"2017","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ctarc.2021.100473_bib0058","doi-asserted-by":"crossref","first-page":"142","DOI":"10.3389\/fonc.2017.00142","article-title":"Implications of MicroRNAs in oncolytic virotherapy","volume":"7","author":"Bofill-De Ros","year":"2017","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0059","doi-asserted-by":"crossref","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","article-title":"Talimogene laherparepvec improves durable response rate in patients with advanced melanoma","volume":"33","author":"Andtbacka","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0060","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1080\/21645515.2017.1412896","article-title":"Talimogene laherparepvec: first in class oncolytic virotherapy","volume":"14","author":"Conry","year":"2018","journal-title":"Hum. Vaccin. Immunother."},{"key":"10.1016\/j.ctarc.2021.100473_bib0061","doi-asserted-by":"crossref","first-page":"475","DOI":"10.3389\/fonc.2020.00475","article-title":"Delivery and biosafety of oncolytic virotherapy","volume":"10","author":"Li","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0062","doi-asserted-by":"crossref","first-page":"3752","DOI":"10.1128\/JVI.02832-12","article-title":"PEGylation of vesicular stomatitis virus extends virus persistence in blood circulation of passively immunized mice","volume":"87","author":"Tesfay","year":"2013","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0063","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/mt.2015.219","article-title":"Perfusion pressure is a critical determinant of the intratumoral extravasation of oncolytic viruses","volume":"24","author":"Miller","year":"2016","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0064","doi-asserted-by":"crossref","first-page":"1870","DOI":"10.1038\/leu.2012.70","article-title":"Curative one-shot systemic virotherapy in murine myeloma","volume":"26","author":"Naik","year":"2012","journal-title":"Leukemia"},{"issue":"2500","key":"10.1016\/j.ctarc.2021.100473_bib0065","article-title":"Clinical activity of systemic VSV-IFN\u03b2-NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma","volume":"39","author":"Cook","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0066","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1038\/leu.2017.120","article-title":"Phase I trial of systemic administration of Edmonston strain of measles virus genetically engineered to express the sodium iodide symporter in patients with recurrent or refractory multiple myeloma","volume":"31","author":"Dispenzieri","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100473_bib0067","doi-asserted-by":"crossref","first-page":"926","DOI":"10.1016\/j.mayocp.2014.04.003","article-title":"Remission of disseminated cancer after systemic oncolytic virotherapy","volume":"89","author":"Russell","year":"2014","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.ctarc.2021.100473_bib0068","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009283","article-title":"MeV-Stealth: a CD46-specific oncolytic measles virus resistant to neutralization by measles-immune human serum","volume":"17","author":"Mu\u00f1oz-Al\u00eda","year":"2021","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.ctarc.2021.100473_bib0069","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1186\/s13046-019-1410-x","article-title":"Graphene oxide arms oncolytic measles virus for improved effectiveness of cancer therapy","volume":"38","author":"Xia","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100473_bib0070","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1007\/s12250-018-0033-2","article-title":"Carrier cells for delivery of oncolytic measles virus into tumors: determinants of efficient loading","volume":"33","author":"Xu","year":"2018","journal-title":"Virol. Sin."},{"key":"10.1016\/j.ctarc.2021.100473_bib0071","doi-asserted-by":"crossref","first-page":"16022","DOI":"10.1038\/mto.2016.22","article-title":"A novel, polymer-coated oncolytic measles virus overcomes immune suppression and induces robust antitumor activity","volume":"3","author":"Nosaki","year":"2016","journal-title":"Mol. Ther. oncolytics"},{"key":"10.1016\/j.ctarc.2021.100473_bib0072","first-page":"47","article-title":"Cell carriers for oncolytic viruses: current challenges and future directions","volume":"2","author":"Roy","year":"2013","journal-title":"Oncolytic Virother."},{"key":"10.1016\/j.ctarc.2021.100473_bib0073","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000981","article-title":"Enhanced immunotherapeutic profile of oncolytic virus-based cancer vaccination using cyclophosphamide preconditioning","volume":"8","author":"Pol","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0074","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1749-6632.2010.05464.x","article-title":"Combination strategies for enhancing the efficacy of immunotherapy in cancer patients","volume":"1194","author":"Moschella","year":"2010","journal-title":"Ann. N. Y. Acad. Sci."},{"key":"10.1016\/j.ctarc.2021.100473_bib0075","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1158\/1078-0432.CCR-20-1565","article-title":"Evolving Status of clinical immunotherapy with oncolytic adenovirus","volume":"27","author":"Farrera-Sal","year":"2021","journal-title":"Clin. cancer Res. an Off. J. Am. Assoc. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100473_bib0076","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1038\/sj.clpt.6100409","article-title":"Preclinical pharmacology and toxicology of intravenous MV-NIS, an oncolytic measles virus administered with or without cyclophosphamide","volume":"82","author":"Myers","year":"2007","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0077","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21207505","article-title":"Clinical application of oncolytic viruses: a systematic review","volume":"21","author":"Cook","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2021.100473_bib0078","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/s41417-018-0074-6","article-title":"JAK\/STAT inhibition with ruxolitinib enhances oncolytic virotherapy in non-small cell lung cancer models","volume":"26","author":"Patel","year":"2019","journal-title":"Cancer Gene. Ther"},{"key":"10.1016\/j.ctarc.2021.100473_bib0079","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112014","article-title":"Inhibitors of the interferon response enhance virus replication in vitro","volume":"9","author":"Stewart","year":"2014","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ctarc.2021.100473_bib0080","doi-asserted-by":"crossref","first-page":"33165","DOI":"10.18632\/oncotarget.5320","article-title":"Vesicular stomatitis virus expressing interferon-\u03b2 is oncolytic and promotes antitumor immune responses in a syngeneic murine model of non-small cell lung cancer","volume":"6","author":"Patel","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2021.100473_bib0081","doi-asserted-by":"crossref","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0082","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/rmv.430","article-title":"Measles virus receptors: SLAM and CD46","volume":"14","author":"Dhiman","year":"2004","journal-title":"Rev. Med. Virol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0083","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/j.exphem.2006.03.002","article-title":"Oncolytic measles virus targets high CD46 expression on multiple myeloma cells","volume":"34","author":"Ong","year":"2006","journal-title":"Exp. Hematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0084","doi-asserted-by":"crossref","DOI":"10.3390\/v8100294","article-title":"Measles to the Rescue: a Review of Oncolytic Measles virus","volume":"8","author":"Aref","year":"2016","journal-title":"Viruses"},{"key":"10.1016\/j.ctarc.2021.100473_bib0085","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1080\/14712598.2017.1288713","article-title":"Potential and clinical translation of oncolytic measles viruses","volume":"17","author":"Robinson","year":"2017","journal-title":"Expert Opin. Biol. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0086","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1182\/blood.V98.7.2002","article-title":"Systemic therapy of myeloma xenografts by an attenuated measles virus","volume":"98","author":"Peng","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0087","doi-asserted-by":"crossref","first-page":"1641","DOI":"10.1182\/blood-2003-07-2233","article-title":"Image-guided radiovirotherapy for multiple myeloma using a recombinant measles virus expressing the thyroidal sodium iodide symporter","volume":"103","author":"Dingli","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0088","series-title":"Mayo Clin. Proc.","article-title":"Oncolytic measles virotherapy and opposition to measles vaccination","author":"Russell","year":"2019"},{"key":"10.1016\/j.ctarc.2021.100473_bib0089","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.molmed.2004.03.003","article-title":"Vesicular stomatitis virus: re-inventing the bullet","volume":"10","author":"Lichty","year":"2004","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0090","doi-asserted-by":"crossref","first-page":"8843","DOI":"10.1128\/JVI.77.16.8843-8856.2003","article-title":"Development of recombinant vesicular stomatitis viruses that exploit defects in host defense to augment specific oncolytic activity","volume":"77","author":"Obuchi","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0091","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1214441110","article-title":"LDL receptor and its family members serve as the cellular receptors for vesicular stomatitis virus","volume":"110","author":"Finkelshtein","year":"2013","journal-title":"Proc. Natl. Acad. Sci"},{"key":"10.1016\/j.ctarc.2021.100473_bib0092","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1146\/annurev-virology-092818-015756","article-title":"Interferon-stimulated genes: what do they all do?","volume":"6","author":"Schoggins","year":"2019","journal-title":"Annu. Rev. Virol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0093","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/77558","article-title":"Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus","volume":"6","author":"Stojdl","year":"2000","journal-title":"Nat. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0094","article-title":"Oncolytic viral therapy for human pancreatic cancer cells by reovirus","volume":"9","author":"Etoh","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100473_bib0095","doi-asserted-by":"crossref","first-page":"3023","DOI":"10.1038\/onc.2011.478","article-title":"Reovirus therapy stimulates endoplasmic reticular stress, NOXA induction, and augments bortezomib-mediated apoptosis in multiple myeloma","volume":"31","author":"Kelly","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2021.100473_bib0096","article-title":"Oncolytic viral therapy for human pancreatic cancer cells by reovirus","volume":"9","author":"Etoh","year":"2003","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100473_bib0097","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2096","article-title":"The role of junctional adhesion molecules in vascular inflammation","volume":"7","author":"Weber","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0098","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/leu.2017.287","article-title":"JAM-A as a prognostic factor and new therapeutic target in multiple myeloma","volume":"32","author":"Solimando","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100473_bib0099","doi-asserted-by":"crossref","first-page":"4962","DOI":"10.1158\/1078-0432.CCR-11-3085","article-title":"Reovirus as a viable therapeutic option for the treatment of multiple myeloma","volume":"18","author":"Thirukkumaran","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100473_bib0100","doi-asserted-by":"crossref","first-page":"413","DOI":"10.4161\/auto.22867","article-title":"Reovirus modulates autophagy during oncolysis of multiple myeloma","volume":"9","author":"Thirukkumaran","year":"2013","journal-title":"Autophagy"},{"key":"10.1016\/j.ctarc.2021.100473_bib0101","doi-asserted-by":"crossref","first-page":"41275","DOI":"10.18632\/oncotarget.5753","article-title":"Junctional adhesion molecule-A is overexpressed in advanced multiple myeloma and determines response to oncolytic reovirus","volume":"6","author":"Kelly","year":"2015","journal-title":"Oncotarget"},{"key":"10.1016\/j.ctarc.2021.100473_bib0102","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1038\/leu.2017.272","article-title":"Oncolytic reovirus sensitizes multiple myeloma cells to anti-PD-L1 therapy","volume":"32","author":"Kelly","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2021.100473_bib0103","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001803","article-title":"Reovirus-induced cell-mediated immunity for the treatment of multiple myeloma within the resistant bone marrow niche","volume":"9","author":"M\u00fcller","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0104","doi-asserted-by":"crossref","first-page":"5946","DOI":"10.1158\/1078-0432.CCR-14-1404","article-title":"A phase I trial of single-agent reolysin in patients with relapsed multiple myeloma","volume":"20","author":"Sborov","year":"2014","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctarc.2021.100473_bib0105","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1182\/bloodadvances.2018025593","article-title":"Oncolytic immunotherapy and bortezomib synergy improves survival of refractory multiple myeloma in a preclinical model","volume":"3","author":"Thirukkumaran","year":"2019","journal-title":"Blood Adv."},{"key":"10.1016\/j.ctarc.2021.100473_bib0106","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1158\/1535-7163.MCT-15-0240-T","article-title":"Histone deacetylase inhibitors enhance the therapeutic potential of reovirus in multiple myeloma","volume":"15","author":"Stiff","year":"2016","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0107","unstructured":"Shaw, M.L. & Palese, P. Fields virology 6th. fields virology (2013)."},{"key":"10.1016\/j.ctarc.2021.100473_bib0108","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1111\/j.1365-2141.2007.06550.x","article-title":"Oncolytic Coxsackievirus A21 as a novel therapy for multiple myeloma","volume":"137","author":"Au","year":"2007","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0109","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1186\/s40425-019-0632-y","article-title":"Plasmacytoid dendritic cells orchestrate innate and adaptive anti-tumor immunity induced by oncolytic coxsackievirus A21","volume":"7","author":"M\u00fcller","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0110","doi-asserted-by":"crossref","first-page":"229","DOI":"10.5045\/kjh.2011.46.4.229","article-title":"Adenovirus as a new agent for multiple myeloma therapies: opportunities and restrictions","volume":"46","author":"Raus","year":"2011","journal-title":"Korean J. Hematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0111","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.3390\/v2102196","article-title":"Serotype chimeric human adenoviruses for cancer gene therapy","volume":"2","author":"Ranki","year":"2010","journal-title":"Viruses"},{"key":"10.1016\/j.ctarc.2021.100473_bib0112","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1038\/s41417-020-0176-9","article-title":"Immunostimulatory oncolytic virotherapy for multiple myeloma targeting 4-1BB and\/or CD40","volume":"27","author":"Wenthe","year":"2020","journal-title":"Cancer Gene. Ther."},{"key":"10.1016\/j.ctarc.2021.100473_bib0113","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.3892\/or.2014.3020","article-title":"PI3K inhibitor LY294002 inhibits activation of the Akt\/mTOR pathway induced by an oncolytic adenovirus expressing TRAIL and sensitizes multiple myeloma cells to the oncolytic virus","volume":"31","author":"Tong","year":"2014","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2021.100473_bib0114","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1182\/blood-2018-99-118056","article-title":"Myeloma-specific oncolytic adenovirus induces significant tumour oncolysis in vitro and in vivo and prevents cell line regrowth","volume":"132","author":"Stewart","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2021.100473_bib0115","first-page":"79","article-title":"The effect of attenuated vaccinia virus AS strain on multiple myeloma; a case report","volume":"57","author":"Kawa","year":"1987","journal-title":"Jpn. J. Exp. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0116","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110030","article-title":"Enhancing therapeutic efficacy of oncolytic vaccinia virus armed with Beclin-1, an autophagic Gene in leukemia and myeloma","volume":"125","author":"Lei","year":"2020","journal-title":"Biomed Pharmacother."},{"key":"10.1016\/j.ctarc.2021.100473_bib0117","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.omto.2017.07.001","article-title":"Efficacy and safety of doubly-regulated vaccinia virus in a mouse xenograft model of multiple myeloma","volume":"6","author":"Futami","year":"2017","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.ctarc.2021.100473_bib0118","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3389\/fonc.2020.00860","article-title":"Minimal residual disease in multiple myeloma: current landscape and future applications with immunotherapeutic approaches","volume":"10","author":"Kostopoulos","year":"2020","journal-title":"Front. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0119","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omto.2020.06.011","article-title":"Autologous transplantation using donor leukocytes loaded ex vivo with oncolytic myxoma virus can eliminate residual multiple myeloma","volume":"18","author":"Villa","year":"2020","journal-title":"Mol. Ther. oncolytics"},{"key":"10.1016\/j.ctarc.2021.100473_bib0120","first-page":"1","article-title":"Myxoma virus attenuates expression of activating transcription factor 4 (ATF4) which has implications for the treatment of proteasome inhibitor-resistant multiple myeloma","volume":"4","author":"Dunlap","year":"2015","journal-title":"Oncolytic Virother"},{"key":"10.1016\/j.ctarc.2021.100473_bib0121","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.omto.2021.02.009","article-title":"Oncolytic herpes simplex virus infects myeloma cells in vitro and in vivo","volume":"20","author":"Ghose","year":"2021","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.ctarc.2021.100473_bib0122","first-page":"211","article-title":"Caspase dependent and independent anti-hematological malignancy activity of AMHA1 attenuated newcastle disease virus","volume":"8","author":"Mohammed","year":"2019","journal-title":"Int. J. Mol. Cell Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0123","doi-asserted-by":"crossref","first-page":"4078","DOI":"10.1128\/JVI.02810-15","article-title":"MicroRNA-detargeted mengovirus for oncolytic virotherapy","volume":"90","author":"Ruiz","year":"2016","journal-title":"J. Virol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0124","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13045-020-00919-w","article-title":"Bovine pestivirus is a new alternative virus for multiple myeloma oncolytic virotherapy","volume":"13","author":"Marchica","year":"2020","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0125","first-page":"727","article-title":"PD-1\/PD-L1 pathway: current researches in cancer","volume":"10","author":"Han","year":"2020","journal-title":"Am. J. Cancer Res."},{"key":"10.1016\/j.ctarc.2021.100473_bib0126","doi-asserted-by":"crossref","DOI":"10.1016\/j.prp.2020.153114","article-title":"Immune checkpoint inhibitors in multiple myeloma: a review of the literature","volume":"216","author":"Caserta","year":"2020","journal-title":"Pathol. - Res. Pract."},{"key":"10.1016\/j.ctarc.2021.100473_bib0127","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.immuni.2007.05.016","article-title":"Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses","volume":"27","author":"Butte","year":"2007","journal-title":"Immunity"},{"key":"10.1016\/j.ctarc.2021.100473_bib0128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/emmm.201100165","article-title":"PD-L1 co-stimulation contributes to ligand-induced T cell receptor down-modulation on CD8+ T cells","volume":"3","author":"Karwacz","year":"2011","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0129","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1146\/annurev-pathol-042020-042741","article-title":"Immune checkpoint inhibitors for the treatment of cancer: clinical impact and mechanisms of response and resistance","volume":"16","author":"Bagchi","year":"2021","journal-title":"Annu. Rev. Pathol. Mech. Dis."},{"key":"10.1016\/j.ctarc.2021.100473_bib0130","doi-asserted-by":"crossref","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase Ib study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0131","doi-asserted-by":"crossref","first-page":"e41","DOI":"10.1111\/bjh.15888","article-title":"Phase 1b trial of pembrolizumab monotherapy for relapsed\/refractory multiple myeloma: KEYNOTE-013","volume":"186","author":"Ribrag","year":"2019","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0132","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.cellimm.2018.10.003","article-title":"The challenges of checkpoint inhibition in the treatment of multiple myeloma","volume":"334","author":"Paul","year":"2018","journal-title":"Cell. Immunol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0133","doi-asserted-by":"crossref","first-page":"8627","DOI":"10.3390\/ijms21228627","article-title":"Oncolytic Viruses and Immune Checkpoint Inhibitors: preclinical Developments to Clinical Trials","volume":"21","author":"Hwang","year":"2020","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ctarc.2021.100473_bib0134","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctarc.2021.100473_bib0135","doi-asserted-by":"crossref","first-page":"3192","DOI":"10.1002\/cncr.32909","article-title":"The BiTE (bispecific T-cell engager) platform: development and future potential of a targeted immuno-oncology therapy across tumor types","volume":"126","author":"Einsele","year":"2020","journal-title":"Cancer"},{"key":"10.1016\/j.ctarc.2021.100473_bib0136","doi-asserted-by":"crossref","first-page":"683","DOI":"10.3389\/fimmu.2020.00683","article-title":"Combining Oncolytic Viruses With Cancer Immunotherapy: establishing a New Generation of Cancer Treatment","volume":"11","author":"Shi","year":"2020","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ctarc.2021.100473_bib0137","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-021-00469-5","article-title":"CAR T-cell therapy in multiple myeloma: more room for improvement","volume":"11","author":"Teoh","year":"2021","journal-title":"Blood Cancer J"},{"key":"10.1016\/j.ctarc.2021.100473_bib0138","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/j.omto.2020.03.018","article-title":"Viral Delivery of CAR Targets to Solid Tumors Enables Effective Cell Therapy","volume":"17","author":"Aalipour","year":"2020","journal-title":"Mol. Ther. - Oncolytics"},{"key":"10.1016\/j.ctarc.2021.100473_bib0139","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.15252\/emmm.201707567","article-title":"Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies","volume":"9","author":"Freedman","year":"2017","journal-title":"EMBO Mol. Med."},{"key":"10.1016\/j.ctarc.2021.100473_bib0140","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.it.2019.01.008","article-title":"Cell-Redirecting Strategies to \u2018STAb\u2019 Tumors: beyond CARs and Bispecific Antibodies","volume":"40","author":"Blanco","year":"2019","journal-title":"Trends Immunol"},{"key":"10.1016\/j.ctarc.2021.100473_bib0141","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.3389\/fimmu.2020.02062","article-title":"CRISPR\/Cas: from tumor gene editing to T cell-based immunotherapy of cancer","volume":"11","author":"Azangou-Khyavy","year":"2020","journal-title":"Front. Immunol."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001696?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294221001696?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T06:19:04Z","timestamp":1762841944000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294221001696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021]]},"references-count":141,"alternative-id":["S2468294221001696"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100473","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2021]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Oncolytic virotherapy \u2013 Forging its place in the immunomodulatory paradigm for Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2021.100473","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100473"}}